Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea flag South Korea · Delayed Price · Currency is KRW
29,950
-250 (-0.83%)
Last updated: Sep 19, 2025, 11:37 AM KST

Daihan Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Operating Revenue
207,677204,195195,911184,268171,463166,080
Upgrade
Other Revenue
-0----0-
Upgrade
207,677204,195195,911184,268171,463166,080
Upgrade
Revenue Growth (YoY)
4.86%4.23%6.32%7.47%3.24%-1.59%
Upgrade
Cost of Revenue
138,843134,788130,599124,455115,781109,885
Upgrade
Gross Profit
68,83369,40765,31259,81255,68256,195
Upgrade
Selling, General & Admin
28,98628,42826,94525,44524,92324,892
Upgrade
Research & Development
2,1801,8021,641567.87790.59689.17
Upgrade
Other Operating Expenses
470.16479.63411.75387.26334.4303.68
Upgrade
Operating Expenses
32,28731,32729,51726,84426,61426,232
Upgrade
Operating Income
36,54638,08135,79532,96829,06829,963
Upgrade
Interest Expense
-2.95-1.81-52.47-593.43-469.27-617.06
Upgrade
Interest & Investment Income
1,6961,47587.18486.66506.7421.05
Upgrade
Currency Exchange Gain (Loss)
324.451,229504.71525.35687.03-426.96
Upgrade
Other Non Operating Income (Expenses)
62.091,18487.5773.92599.56822.93
Upgrade
EBT Excluding Unusual Items
38,62641,96736,42233,46130,39230,163
Upgrade
Gain (Loss) on Sale of Investments
547.5303.6288.69---
Upgrade
Gain (Loss) on Sale of Assets
50.9758.0322.53-9.441.2819.72
Upgrade
Asset Writedown
------7,650
Upgrade
Pretax Income
39,22442,32936,73433,45130,43322,532
Upgrade
Income Tax Expense
7,9018,5698,3078,4917,7635,151
Upgrade
Net Income
31,32433,75928,42624,96122,67017,381
Upgrade
Net Income to Common
31,32433,75928,42624,96122,67017,381
Upgrade
Net Income Growth
4.29%18.76%13.88%10.10%30.43%-38.29%
Upgrade
Shares Outstanding (Basic)
666666
Upgrade
Shares Outstanding (Diluted)
666666
Upgrade
Shares Change (YoY)
---1.75%-0.25%--
Upgrade
EPS (Basic)
5327.175741.344834.414170.673778.402896.80
Upgrade
EPS (Diluted)
5327.175741.344834.414170.673778.402896.80
Upgrade
EPS Growth
4.29%18.76%15.92%10.38%30.43%-38.29%
Upgrade
Free Cash Flow
13,77719,84117,58020,37828,76728,267
Upgrade
Free Cash Flow Per Share
2343.093374.382989.793405.014794.574711.20
Upgrade
Gross Margin
33.14%33.99%33.34%32.46%32.48%33.84%
Upgrade
Operating Margin
17.60%18.65%18.27%17.89%16.95%18.04%
Upgrade
Profit Margin
15.08%16.53%14.51%13.55%13.22%10.46%
Upgrade
Free Cash Flow Margin
6.63%9.72%8.97%11.06%16.78%17.02%
Upgrade
EBITDA
44,07245,36244,45942,17640,47941,263
Upgrade
EBITDA Margin
21.22%22.21%22.69%22.89%23.61%24.85%
Upgrade
D&A For EBITDA
7,5277,2828,6639,20811,41111,300
Upgrade
EBIT
36,54638,08135,79532,96829,06829,963
Upgrade
EBIT Margin
17.60%18.65%18.27%17.89%16.95%18.04%
Upgrade
Effective Tax Rate
20.14%20.24%22.61%25.38%25.51%22.86%
Upgrade
Advertising Expenses
-99.7678.6993.6763.1848.89
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.